Last reviewed · How we verify
Low dose chemotherapy
Low dose chemotherapy uses reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing systemic toxicity.
Low dose chemotherapy uses reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing systemic toxicity. Used for Various solid tumors and hematologic malignancies (specific indications dependent on Phase 3 trial design).
At a glance
| Generic name | Low dose chemotherapy |
|---|---|
| Also known as | •Thalidomide •Celecoxib •Etoposide •Cyclophosphamide |
| Sponsor | All India Institute of Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Low dose chemotherapy regimens deliver sub-standard doses of conventional chemotherapeutic drugs, either as monotherapy or in combination, to achieve anti-tumor effects with reduced hematologic and non-hematologic toxicity. This approach is particularly relevant in elderly patients, those with comorbidities, or in metronomic dosing schedules where continuous low-level exposure may enhance anti-angiogenic effects and immune modulation.
Approved indications
- Various solid tumors and hematologic malignancies (specific indications dependent on Phase 3 trial design)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Mucositis
- Infection
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (PHASE2)
- A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer (PHASE2)
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (PHASE1)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |